Malcolm Campbell Memorial Prize
Downloads
Malcolm_Campbell_Call for nominations_2023
Malcolm Campbell Memorial Prize – history
Malcolm Campbell Memorial Prize 2021 – announcement of winners and presentation
Overview
The Malcolm Campbell Memorial Prize is awarded biennially by the RSC BMCS to commemorate Professor Campbell’s outstanding contributions in a broad range of chemistry and their applications to the understanding of bioactivity. The award comprises £2000 and a medal as well as one free attendance at an RSC BMCS conference in the year of the award.
Malcolm Campbell Memorial Prize 2023 – Call for Nominations
The BMCS are now actively seeking nominations for this biennial prize, invited from an individual or team who has made the most significant scientific contribution to biological chemistry. The prize-winner(s) may be from academia or industry, and their work should be timely and contemporaneous. The Prize has a value of £2,000, and is presented at the next RSC/ SCI Cambridge MedChem symposium. Please see the PDF below for more information.
Criteria
Submissions are invited from individuals or teams in industry and academia with a British research centre mailing address although work may be from several worldwide groups.
Seminal publications which may include presentations in the public domain and/or patents from the submitting individual or team relating to work of biological and/or medicinal chemistry interest including discovery, process development, agrochemical and aromachemical research.
Submissions may be a culmination of a series of papers published in recent years prior to the award.
Submissions must be accompanied by written permission from Heads of Department or Managers for the release of the work details.
All submissions should be sent to the Conference Secretariat, Hg3 Conferences.
The closing date for the 2023 Memorial Prize 1s 31st October 2022.
The prize was received by the UK Government Chief Scientific Adviser, Sir Patrick Vallance FRS FMedSci FRCP, at the 21st RSC/SCI Medicinal Chemistry Symposium, Cambridge UK held on 13th – 15th September 2021 on behalf of British scientists and clinical researchers who contributed to the COVID-19 response. The prize also recognises the countless numbers of healthcare staff and clinical study volunteers who have selflessly dedicated themselves to the pursuit of patient care and the development of drugs and vaccines for COVID-19.
Much of the ability of British science to respond to the pandemic arose through years of commitment to basic biomedical research, notably the world-leading capability in genome sequencing, the development of vaccine platform technologies, and deep expertise in drug discovery and development.
During the course of 2020 British scientists: pioneered genomic evaluation of COVID-19 to trace viral mutations and monitor spread of the pandemic; initiated clinical studies to evaluate rapidly a range of existing drugs in COVID patients resulting in the discovery that dexamethasone has a significant benefit on mortality in critically ill COVID patients; fast-tracked the development of vaccine candidates resulting in regulatory approval by the end of 2020. These achievements, and investments in further basic research, will have a lasting impact on the global management of COVID-19 throughout 2021 and beyond.
The Malcolm Campbell Memorial Prize is awarded biennially by the Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry to commemorate Professor Campbell’s outstanding contributions in a broad range of chemistry and their applications to biomedical science.
Malcolm Campbell Memorial Prize – Previous Winners
2021
British scientists and clinical researchers who contributed to the COVID-19 response (received on their behalf by Sir Patrick Vallance, Chief Scientific Adviser to the Government of the UK)
2019
The FGFR discovery team: Christopher W Murray, Patrick Angibaud, and Herbie Newell
Astex Pharmaceuticals, Janssen Pharmaceutica, and the Northern Institute for Cancer Research (NICR), Newcastle University
Development of Erdafitinib
2017
Osimertinib Team
AstraZeneca
Development of TAGRISSOTM
2015
Miles Congreve, Fiona Marshall and Malcom Weir
Heptares
GPCR drug discovery
2013
BrilintaTM/BriliqueTM Team
AstraZeneca
Development of BrilintaTM/BriliqueTM
2011
Paul O’Neill, Kevin Park and Stephen Ward
University of Liverpool
Research and Development of Anti-Malaria Agents
2009
Lawrence Woo and Barry Potter
University of Bath
Atul Purohit and Michael Reed
Imperial College, London
Discovery of Steroid Sulfatase Inhibitors
2007
Jonathan Bennett, Anton Bom, Alan Muir, Ronald Palin, David Rees and Ming Zhang
Organon
Development of Sugammadex
2005§
David O’Hagan
University of St Andrews
Research on Fluorinating Enzymes
2005§
Tony Wood
Pfizer
Development of CCR5 Antagonists
2003
Malcolm Stevens, Andrew Westwell & Tracy Bradshaw
Cancer Research UK
Discovery of the Anticancer Compound Fortress & Related Work
§ Joint winners
A history of the Prize is available to download.